Of interest, these same resistance pathways are known to be altered when breast cancers become resistant to other cancer therapeutic agents such as CDK4/6 inhibitors, endocrine agents such as tamoxifen, or DNA damaging radiation or chemotherapies [12,13,14,15,16,17,18], although our findings also reveal that the FOXM1 inhibitors show some distinct differences in mechanisms of resistance. Here, FOXM1 is linked to breast carcinoma.